Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent

BMC Medical Genetics

Volumn 14, Issue 1, 2013, Pages

  Tischkowitz, Marc ^a,b,c   Sabbaghian, Nelly ^a,b   Hamel, Nancy ^d   Pouchet, Carly ^e   Foulkes, William D ^a,b,d,e   Mes Masson, Anne Marie ^f,g   Provencher, Diane M ^f,g   Tonin, Patricia N ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Breast cancer risk; Founder mutations; French Canadians; Hereditary breast cancer; Ovarian cancer; p.Q775; p.Q775X; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MEMBRANE PROTEIN; PROTEIN PALB2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER RISK; CANCER SUSCEPTIBILITY; DEMOGRAPHY; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION;

ADULT; AGED; BASE SEQUENCE; BREAST NEOPLASMS; CANADA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PEDIGREE; TUMOR SUPPRESSOR PROTEINS;

EID: 84872023611     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-14-5     Document Type: Article

References (35)

1. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 2009, 114(3):457-462. 10.1007/s10549-008-0036-z, 18446436.
2. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011, 71(6):2222-2229. 10.1158/0008-5472.CAN-10-3958, 3059378, 21285249.
3. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J. A novel germline PALB2 deletion in polish breast and ovarian cancer patients. BMC Med Genet 2010, 11:20. 2829009, 20122277.
4. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, et al. A recurrent mutation in PALB2 in finnish cancer families. Nature 2007, 446(7133):316-319. 10.1038/nature05609, 17287723.
5. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in french-canadian women. Breast Cancer Res 2007, 9(6):R83. 10.1186/bcr1828, 2246183, 18053174.
6. Garcia MJ, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, Blanco I, Caldes T, de la Hoya M, Ramon YCT, et al. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative spanish breast cancer families. Breast Cancer Res Treat 2009, 113(3):545-551. 10.1007/s10549-008-9945-0, 18302019.
7. Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D. A PALB2 germline mutation associated with hereditary breast cancer in italy. Fam Cancer 2010, 9(2):181-185. 10.1007/s10689-009-9295-z, 19763884.
8. Sluiter M, Mew S, van Rensburg EJ. PALB2 Sequence variants in young south african breast cancer patients. Fam Cancer 2009, 8(4):347-353. 10.1007/s10689-009-9241-0, 19333784.
9. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and fanconi anemia. Cancer Res 2010, 70(19):7353-7359. 10.1158/0008-5472.CAN-10-1012, 2948578, 20858716.
10. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 2007, 104(16):6788-6793. 10.1073/pnas.0701724104, 1871863, 17420451.
11. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006, 22(6):719-729. 10.1016/j.molcel.2006.05.022, 16793542.
12. Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 2010, 20(3):268-276. 10.1016/j.gde.2010.02.009, 20346647.
13. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et al. PALB2, Which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39(2):165-167. 10.1038/ng1959, 2871593, 17200668.
14. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008, 359(20):2143-2153. 10.1056/NEJMra0802968, 19005198.
15. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324(5924):217. 10.1126/science.1171202, 2684332, 19264984.
16. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009, 137(3):1183-1186. 10.1053/j.gastro.2009.06.055, 19635604.
17. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee MP, Tavtigian S, Concannon P, Foulkes WD, Bernstein JL, et al. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 2012, 33(4):674-680. 10.1002/humu.22022, 22241545.
18. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, Mitchell GA. Population history and its impact on medical genetics in quebec. Clin Genet 2005, 68(4):287-301. 10.1111/j.1399-0004.2005.00497.x, 16143014.
19. Scriver CR. Human genetics: lessons from quebec populations. Annu Rev Genomics Hum Genet 2001, 2:69-101. 10.1146/annurev.genom.2.1.69, 11701644.
20. Tonin PN. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the french canadian breast and breast-ovarian cancer families, a founder population of quebec, canada]. Bull Cancer 2006, 93(9):841-846.
21. Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, Ghadirian P, Provencher D, Tonin PN. Comprehensive BRCA1 and BRCA2 mutation analyses and review of french canadian families with at least three cases of breast cancer. Fam Cancer 2010, 9(4):507-517. 10.1007/s10689-010-9372-3, 20694749.
22. Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, et al. The BRCA2 c.9004 G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of french canadian descent. Breast Cancer Res Treat 2012, 131(1):333-340. 10.1007/s10549-011-1796-4, 21947752.
23. Oros KK, Ghadirian P, Greenwood CM, Perret C, Shen Z, Paredes Y, Arcand SL, Mes-Masson AM, Narod SA, Foulkes WD, et al. Significant proportion of breast and/or ovarian cancer families of french canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004, 112(3):411-419. 10.1002/ijc.20406, 15382066.
24. Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of french canadian descent. Clin Genet 2006, 70(4):320-329. 10.1111/j.1399-0004.2006.00673.x, 16965326.
25. Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Founder BRCA1 and BRCA2 mutations in french canadian breast and ovarian cancer families. Am J Hum Genet 1998, 63(5):1341-1351. 10.1086/302099, 1377544, 9792861.
26. Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, Ghadirian P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in french canadian hereditary breast and/ovarian cancer families. BMC Med Genet 2006, 7:23. 1464093, 16539696.
27. Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson AM, et al. Haplotype analysis of BRCA2 8765delAG mutation carriers in french canadian and yemenite jewish hereditary breast cancer families. Hum Hered 2001, 52(2):116-120. 10.1159/000053364, 11512557.
28. Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, Chiquette J, Plante M, Laframboise R, Lepine J, et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk french-canadian breast/ovarian cancer families. Hum Genet 2005, 117(2-3):119-132.
29. Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, et al. The contribution of founder mutations to early-onset breast cancer in french-canadian women. Clin Genet 2009, 76(5):421-426. 10.1111/j.1399-0004.2009.01277.x, 19863560.
30. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 2011, 6(12):e28250. 10.1371/journal.pone.0028250, 3232202, 22163003.
31. Guenard F, Pedneault CS, Ouellette G, Labrie Y, Simard J, Durocher F. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 french canadian families with high risk of breast cancer. Genet Test Mol Biomarkers 2010, 14(4):515-526. 10.1089/gtmb.2010.0027, 20722467.
32. Gagnon A, Heyer E. Fragmentation of the quebec population genetic pool (canada): evidence from the genetic contribution of founders per region in the 17th and 18th centuries. Am J Phys Anthropol 2001, 114(1):30-41. 10.1002/1096-8644(200101)114:1<30::AID-AJPA1003>3.0.CO;2-L, 11150050.
33. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011, 108(44):18032-18037. 10.1073/pnas.1115052108, 3207658, 22006311.
34. Prokofyeva D, Bogdanova N, Bermisheva M, Zinnatullina G, Hillemanns P, Khusnutdinova E, Dork T. Rare occurrence of PALB2 mutations in ovarian cancer patients from the volga-ural region. Clin Genet 2012, 82(1):100-101. 10.1111/j.1399-0004.2011.01824.x, 22310028.
35. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008, 68(4):998-1002. 10.1158/0008-5472.CAN-07-2418, 18281473.